Diabetes autoantibodies do not predict progression to diabetes in adults: The Diabetes Prevention Program

D. Dabelea, Y. Ma, W. C. Knowler, S. Marcovina, C. D. Saudek, R. Arakaki, N. H. White, S. E. Kahn, T. J. Orchard, Ronald B Goldberg, J. Palmer, R. F. Hamman

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aims: To determine if the presence of diabetes autoantibodies predicts the development of diabetes among participants in the Diabetes Prevention Program. Methods: A total of 3050 participants were randomized into three treatment groups: intensive lifestyle intervention, metformin and placebo. Glutamic acid decarboxylase (GAD) 65 autoantibodies and insulinoma-associated-2 autoantibodies were measured at baseline and participants were followed for 3.2 years for the development of diabetes. Results: The overall prevalence of GAD autoantibodies was 4.0%, and it varied across racial/ethnic groups from 2.4% among Asian-Pacific Islanders to 7.0% among non-Hispanic black people. There were no significant differences in BMI or metabolic variables (glucose, insulin, HbA1c, estimated insulin resistance, corrected insulin response) stratified by baseline GAD antibody status. GAD autoantibody positivity did not predict diabetes overall (adjusted hazard ratio 0.98; 95% CI 0.56-1.73) or in any of the three treatment groups. Insulinoma-associated-2 autoantibodies were positive in only one participant (0.033%). Conclusions: These data suggest that 'diabetes autoimmunity', as reflected by GAD antibodies and insulinoma-associated-2 autoantibodies, in middle-aged individuals at risk for diabetes is not a clinically relevant risk factor for progression to diabetes.

Original languageEnglish
Pages (from-to)1064-1068
Number of pages5
JournalDiabetic Medicine
Volume31
Issue number9
DOIs
StatePublished - Jan 1 2014

Fingerprint

Autoantibodies
Glutamate Decarboxylase
Insulinoma
Insulin
Antibodies
Metformin
Autoimmunity
Ethnic Groups
Insulin Resistance
Life Style
Placebos
Glucose
Therapeutics

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Dabelea, D., Ma, Y., Knowler, W. C., Marcovina, S., Saudek, C. D., Arakaki, R., ... Hamman, R. F. (2014). Diabetes autoantibodies do not predict progression to diabetes in adults: The Diabetes Prevention Program. Diabetic Medicine, 31(9), 1064-1068. https://doi.org/10.1111/dme.12437

Diabetes autoantibodies do not predict progression to diabetes in adults : The Diabetes Prevention Program. / Dabelea, D.; Ma, Y.; Knowler, W. C.; Marcovina, S.; Saudek, C. D.; Arakaki, R.; White, N. H.; Kahn, S. E.; Orchard, T. J.; Goldberg, Ronald B; Palmer, J.; Hamman, R. F.

In: Diabetic Medicine, Vol. 31, No. 9, 01.01.2014, p. 1064-1068.

Research output: Contribution to journalArticle

Dabelea, D, Ma, Y, Knowler, WC, Marcovina, S, Saudek, CD, Arakaki, R, White, NH, Kahn, SE, Orchard, TJ, Goldberg, RB, Palmer, J & Hamman, RF 2014, 'Diabetes autoantibodies do not predict progression to diabetes in adults: The Diabetes Prevention Program', Diabetic Medicine, vol. 31, no. 9, pp. 1064-1068. https://doi.org/10.1111/dme.12437
Dabelea, D. ; Ma, Y. ; Knowler, W. C. ; Marcovina, S. ; Saudek, C. D. ; Arakaki, R. ; White, N. H. ; Kahn, S. E. ; Orchard, T. J. ; Goldberg, Ronald B ; Palmer, J. ; Hamman, R. F. / Diabetes autoantibodies do not predict progression to diabetes in adults : The Diabetes Prevention Program. In: Diabetic Medicine. 2014 ; Vol. 31, No. 9. pp. 1064-1068.
@article{4666cac1d011496bb2912c541a642084,
title = "Diabetes autoantibodies do not predict progression to diabetes in adults: The Diabetes Prevention Program",
abstract = "Aims: To determine if the presence of diabetes autoantibodies predicts the development of diabetes among participants in the Diabetes Prevention Program. Methods: A total of 3050 participants were randomized into three treatment groups: intensive lifestyle intervention, metformin and placebo. Glutamic acid decarboxylase (GAD) 65 autoantibodies and insulinoma-associated-2 autoantibodies were measured at baseline and participants were followed for 3.2 years for the development of diabetes. Results: The overall prevalence of GAD autoantibodies was 4.0{\%}, and it varied across racial/ethnic groups from 2.4{\%} among Asian-Pacific Islanders to 7.0{\%} among non-Hispanic black people. There were no significant differences in BMI or metabolic variables (glucose, insulin, HbA1c, estimated insulin resistance, corrected insulin response) stratified by baseline GAD antibody status. GAD autoantibody positivity did not predict diabetes overall (adjusted hazard ratio 0.98; 95{\%} CI 0.56-1.73) or in any of the three treatment groups. Insulinoma-associated-2 autoantibodies were positive in only one participant (0.033{\%}). Conclusions: These data suggest that 'diabetes autoimmunity', as reflected by GAD antibodies and insulinoma-associated-2 autoantibodies, in middle-aged individuals at risk for diabetes is not a clinically relevant risk factor for progression to diabetes.",
author = "D. Dabelea and Y. Ma and Knowler, {W. C.} and S. Marcovina and Saudek, {C. D.} and R. Arakaki and White, {N. H.} and Kahn, {S. E.} and Orchard, {T. J.} and Goldberg, {Ronald B} and J. Palmer and Hamman, {R. F.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/dme.12437",
language = "English",
volume = "31",
pages = "1064--1068",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Diabetes autoantibodies do not predict progression to diabetes in adults

T2 - The Diabetes Prevention Program

AU - Dabelea, D.

AU - Ma, Y.

AU - Knowler, W. C.

AU - Marcovina, S.

AU - Saudek, C. D.

AU - Arakaki, R.

AU - White, N. H.

AU - Kahn, S. E.

AU - Orchard, T. J.

AU - Goldberg, Ronald B

AU - Palmer, J.

AU - Hamman, R. F.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Aims: To determine if the presence of diabetes autoantibodies predicts the development of diabetes among participants in the Diabetes Prevention Program. Methods: A total of 3050 participants were randomized into three treatment groups: intensive lifestyle intervention, metformin and placebo. Glutamic acid decarboxylase (GAD) 65 autoantibodies and insulinoma-associated-2 autoantibodies were measured at baseline and participants were followed for 3.2 years for the development of diabetes. Results: The overall prevalence of GAD autoantibodies was 4.0%, and it varied across racial/ethnic groups from 2.4% among Asian-Pacific Islanders to 7.0% among non-Hispanic black people. There were no significant differences in BMI or metabolic variables (glucose, insulin, HbA1c, estimated insulin resistance, corrected insulin response) stratified by baseline GAD antibody status. GAD autoantibody positivity did not predict diabetes overall (adjusted hazard ratio 0.98; 95% CI 0.56-1.73) or in any of the three treatment groups. Insulinoma-associated-2 autoantibodies were positive in only one participant (0.033%). Conclusions: These data suggest that 'diabetes autoimmunity', as reflected by GAD antibodies and insulinoma-associated-2 autoantibodies, in middle-aged individuals at risk for diabetes is not a clinically relevant risk factor for progression to diabetes.

AB - Aims: To determine if the presence of diabetes autoantibodies predicts the development of diabetes among participants in the Diabetes Prevention Program. Methods: A total of 3050 participants were randomized into three treatment groups: intensive lifestyle intervention, metformin and placebo. Glutamic acid decarboxylase (GAD) 65 autoantibodies and insulinoma-associated-2 autoantibodies were measured at baseline and participants were followed for 3.2 years for the development of diabetes. Results: The overall prevalence of GAD autoantibodies was 4.0%, and it varied across racial/ethnic groups from 2.4% among Asian-Pacific Islanders to 7.0% among non-Hispanic black people. There were no significant differences in BMI or metabolic variables (glucose, insulin, HbA1c, estimated insulin resistance, corrected insulin response) stratified by baseline GAD antibody status. GAD autoantibody positivity did not predict diabetes overall (adjusted hazard ratio 0.98; 95% CI 0.56-1.73) or in any of the three treatment groups. Insulinoma-associated-2 autoantibodies were positive in only one participant (0.033%). Conclusions: These data suggest that 'diabetes autoimmunity', as reflected by GAD antibodies and insulinoma-associated-2 autoantibodies, in middle-aged individuals at risk for diabetes is not a clinically relevant risk factor for progression to diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84906221388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906221388&partnerID=8YFLogxK

U2 - 10.1111/dme.12437

DO - 10.1111/dme.12437

M3 - Article

C2 - 24646311

AN - SCOPUS:84906221388

VL - 31

SP - 1064

EP - 1068

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 9

ER -